# Triple-Targeting T-Cell Engager Aims to Kill the Plasma Cells Other Therapies Spare - Date: 2026-03-25 - Category: Biotech & Life Sciences Kali Therapeutics' experimental drug KT501 entered human testing on March 18, 2026 — the first patient dosed in a Phase Ia study in rheumatoid arthritis — and within hours, Sanofi confirmed it had secured the worldwide license. ---